Hypercalcemia of Malignancy: Simultaneous Elevation in Parathyroid Hormone-Related Peptide and 1,25 Dihydroxyvitamin D in Sarcoma.

Autor: Kim DW; Division of General Internal Medicine, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland., Miller A; Division of Endocrinology, Diabetes, and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland., Li A; Division of General Internal Medicine, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland., Hardy N; Division of Pathology, University of Maryland School of Medicine, Baltimore, Maryland., Silver KD; Division of Endocrinology, Diabetes, and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.
Jazyk: angličtina
Zdroj: AACE clinical case reports [AACE Clin Case Rep] 2021 Jan 07; Vol. 7 (3), pp. 169-173. Date of Electronic Publication: 2021 Jan 07 (Print Publication: 2021).
DOI: 10.1016/j.aace.2020.11.037
Abstrakt: Objective: Hypercalcemia is a common finding in patients who have an underlying malignancy. Only a few cases of hypercalcemia of malignancy have been linked to more than one mechanism of hypercalcemia. Here, we present a patient with liposarcoma and hypercalcemia of malignancy in the setting of simultaneous elevations in parathyroid hormone-related peptide (PTHrP) and 1,25 dihydroxyvitamin D [1,25(OH) 2 D] levels. Sarcoma-associated hypercalcemia is a rare disorder.
Methods: The patient was an 89-year-old woman with sarcoma-associated hypercalcemia. Multiple mechanisms were uncovered, and treatments were adjusted for them. Literature search for hypercalcemia of malignancy with multiple mechanisms was conducted.
Results: This is the first report describing dual mechanisms of sarcoma-associated hypercalcemia and only the fifth report on PTHrP and 1,25(OH) 2 D simultaneously causing hypercalcemia of malignancy.
Conclusion: Based on this finding, we recommend measuring the 1,25(OH) 2 D levels in conjunction with the PTHrP level in patients with malignancy as this would allow for a more proactive approach to the diagnosis and treatment of hypercalcemia of malignancy.
(© 2021Published by Elsevier Inc. on behalf of the AACE.)
Databáze: MEDLINE
Externí odkaz: